Key Takeaways HIMS reached 2.4 million subscribers in first-quarter 2025, up 38.4% year over year. HIMS drove $576.4 million in online revenues, 115.3% higher than the prior year. HIMS' deferred revenues hit $110.8 million, reflecting strength in prepaid services and future growth.The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS) , has cemented its position as a leading direct-to-consumer healthcare platform by leveraging a subscription-based revenue model at the core of its opera ...

公司表现 - Hims & Hers Health股票在过去一年中上涨161% [1] - 3月和4月的显著抛售为多头提供了机会 [1] 分析师背景 - 分析师Nikolaos Sismanis拥有银行与金融学士学位及五年股票分析师经验 [1] - 分析师覆盖多种成长股和收益股，专注于高预期回报潜力和安全边际的股票 [1] - 分析师为投资服务Wheel of Fortune贡献内容，提供跨资产类别、行业和领域的可操作交易想法 [1] 投资服务 - Wheel of Fortune服务提供一站式投资和组合想法，包括教育内容和实时聊天室 [1] - 服务包含针对非活跃投资者的Funds Macro Portfolio（仅ETF和CEF）和针对活跃投资者的Single Macro Portfolio（侧重单一股票） [1]

Hims & Hers Health, Inc. (HIMS) closed at $55.25 in the latest trading session, marking a -2.83% move from the prior day. This change lagged the S&P 500's 0.55% gain on the day. At the same time, the Dow added 0.25%, and the tech-heavy Nasdaq gained 0.63%.Coming into today, shares of the company had gained 2.99% in the past month. In that same time, the Medical sector gained 3.49%, while the S&P 500 gained 6.29%.Market participants will be closely following the financial results of Hims & Hers Health, Inc. ...

Hims & Hers Health, Inc. (HIMS) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.The upward trend in estimate revisions for this company reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends ...

Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (HIMS 6.96%) may finally be succeeding in cracking the code. The online telehealth platform focuses on circumventing the insurance market; its business of selling affordable medications directly to individuals is growing like a weed, and expects to generate $6.5 billion in revenue by 2030.It has had a tumultuous start to 2025, as Hims & Hers waged a battle to sell new weight loss medications on its online marketplace. ...

Shares of Hims & Hers have crushed the market over the last year.When it comes to stocks that continue to beat the market, my guess is that your mind goes straight to companies leading the charge in artificial intelligence (AI). Sure, stocks such as Palantir Technologies or CoreWeave remain red-hot in a strong technology sector.But smart investors understand that there are myriad opportunities beyond the usual suspects in tech. One company that has emerged as a new favorite among investors is telemedicine b ...

Telehealth has gone through a major boom-and-bust cycle. One promising stock emerging from the bust is Hims & Hers (HIMS 6.75%). Through nifty marketing and an insurance-circumventing subscription model that delivers medicine directly to your front door, the company is taking a lot of share in the telehealth market. The stock has traded up 449% since going public, and it is up a staggering 158% in the past year.Disruptive innovation helped bring shareholders of Hims & Hers stock major gains. But does that m ...

Key Takeaways Hims The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS) , has been leveraging existing capabilities and continuing to expand capabilities to penetrate new sales channels and further improve operations. Per management, HIMS’ model has been developed to be scalable and applicable across new markets and languages. The company expanded into the U.K. in early 2021, and in June 2021, it completed the acquisition of U.K.-based Honest Health Limited, which is now Hims & Hers UK ...

One of the most exciting growth stories in the market is that of Hims & Hers Health Inc. NYSE: HIMS. This company has combined the growth and efficiency aspects of the technology sector with the safety and stability of the medical sector. With this mixture in the business model, investors have the best of both worlds, allowing them to move forward with further upside potential. Hims & Hers Health Today HIMS Hims & Hers Health $53.78 -0.95 (-1.74%) $72.98 P/E Ratio 122.23 Price Target $38.00 Add to Watchlist ...

*Stock prices used were end-of-day prices of June 3, 2025. The video was published on June 4, 2025. Hims & Hers is expanding into Europe in a global push the company previewed earlier this year. Hims & Hers (HIMS -1.76%) is using some of its recent $1 billion capital raise to buy ZAVA, a European healthcare company. In this video, Travis Hoium explains why this will keep the company's revenue growing at an incredible pace. ...